Early responses for BCMA-directed CAR-T cell therapy in progressive MM after 1-3 prior lines of therapy
Mounzer Agha, director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center, present data from CARTITUDE-2 study for patients with Multiple Myeloma, who had received 1–3 prior lines of therapy. In the CARTITUDE-2 study, the patients were treated with Ciltacabtagene autoleucel – a chimeric antigen receptor T (CAR-T) cell therapy expressing two B-cell maturation antigen (BCMA)-targeting, single-domain antibodies designed to confer avidity.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in